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Highlights 
 Storage at 25°C of diluted infliximab solutions did not increase aggregation levels 
 Chemical instability of diluted infliximab was the main limiting factor at 25°C 
 A single freeze-thawing cycle of diluted infliximab caused significant instability 
 Diluted Infliximab solutions were physicochemically stable 90 days at 5°C 
Abstract 
Infliximab is a monoclonal antibody widely used for the treatment of inflammatory diseases. Over the 
past few years, many studies have assessed that monoclonal antibodies are prone to aggregation under 
stress conditions, such as temperature changes and agitation. The aim of this study was to assess stability 
of infliximab (Inflectra®) solutions at different concentrations. These solutions were separately submitted 
to three temperature conditions that are likely to happen during the drug dispensing system: -20°C, 5°C 
and 25°C. To perform a complete characterization of infliximab physicochemical and structural stability a 
wide range of analytical techniques were employed including: visual inspection, subvisible particles 
counting (HIAC), dynamic light scattering (DLS), size exclusion chromatography (SEC), cation exchange 
chromatography (CEX), and analysis of primary, secondary and tertiary structure. When stored at 25°C 
and 5°C CEX was the main limiting factor, while SEC showed only some acceptable variation. After a single 
freeze-thawing cycle, the amount of subvisible particles was significantly increased. Some variations were 
also visible in CEX and hydrodynamic diameter was increased after thawing 10 mg/mL samples. In regard 
of these results, infliximab (Inflectra®) solutions should not be used after a single freeze-thawing cycle 
between reconstitution and administration to the patient. The results showed a stability at 5°C of up to 
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14 days for 10 mg/mL solutions and 90 days for 0.4 and 2 mg/mL solutions, whilst samples stored at 25°C 
were stable only 7 days in original glass vials and 30 days when diluted. 
1. Introduction 
For several years now, treatments based on biological molecules have become ever more 
established as key therapeutic approaches. Infliximab is an IgG1 monoclonal antibody (mAb) that binds 
and inhibits transmembrane and soluble forms of Tumor Necrosis Factor alpha (TNF-α). It is widely used 
in rheumatology for the treatment of rheumatoid arthritis in association with methotrexate, spondylitis 
ankylosing and psoriatic arthritis, and in gastroenterology for Crohn’s Disease and ulcerative colitis and in 
dermatology for psoriasis. In 2013, infliximab CT-P23 became the first biosimilar monoclonal antibody 
approved by the EMA [1] and by the FDA in 2016 [2].  
In a stability study one of the keys is to quantify the active substance and highlight any type of 
degradation that could alter the integrity of the studied molecule, and analytical techniques therefore 
play an essential role in this kind of studies. Yet, the stability of monoclonal antibodies (mAbs) is rather 
complex to assess due to the multiples degradation pathways. Infliximab, like other mAbs and 
biopharmaceutical drugs, is susceptible to many factors that can affect its stability in solution, such as 
temperature [3,4], pH, oxidation [5] and agitation [6]. Degradation of mAbs can be physical or chemical 
more or less related to structural modifications. Even if the complete mechanism has not been fully 
described yet, monoclonal antibodies are also well known for their tendency to form aggregates under 
stress conditions [3,7]. Aggregation of mAbs occurs at different level and no lone analysis is able to 
completely evaluate the whole phenomenon. Different analytical techniques bring specific information 
about nanoparticles, subvisible particles or aggregates molecular weight for example. All these 
techniques supplement one another and should be associated in order to increase the level of evidence, 
and a recent European consensus recommends the use of several analytical techniques to assess their 
physicochemical stability [8]. Pharmaceutical industries have enhanced the formulation of their biological 
drugs to slow down quantitative and qualitative modifications and thus extend their stability, following 
ICH guidelines [9–11].  Forced degradation studies also give information upon degradation mechanisms 
but are not always representative of what happens in real use conditions [12]. There is a lack of data on 
the long term storage of the Mabs and such studies are difficult to perform due to the high cost of this 
kind of drugs, thus depriving healthcare practitioners of critical information about mAbs stability in 
clinical use conditions.  
Stability of reconstituted and diluted infliximab solutions is set up to 24h for both biosimilars 
(according to summary of product characteristics of both REMSIMA®[3] and INFLECTRA®[4]), limited by a 
hypothetically short microbiological stability. But when prepared in controlled atmosphere area 
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microbiological stability is less of an issue, and overall stability depends on the limits of physicochemical 
stability. 
The aim of this study was to evaluate the physicochemical stability of a biosimilar mAb (infliximab 
INFLECTRA®) for a wide concentration range at different storage temperatures, such as those possibly 
encountered in clinical situations for up to 90 days, using complementary analytical assays in order to 
understand the limits of mAb conservation in clinical settings. 
2. Materials and methods 
2.1 Materials and reagents 
Inflectra® powder for solution for infusion (batch 2485036, expire on 09/30/2020) was provided 
for free of charge by Pfizer France SAS (Meudon, France). Sterile water for injection (Ecoflac®) was 
purchased from B Braun Medical (SAS, Boulogne Billancourt Cedex, France) and sodium chloride 0.9% 
infusion bags were purchased from Fresenius Kabi (Louviers, France). Sodium sulfate (Na2SO4), disodium 
phosphate (Na2HPO4), sodium azide (NaN3), 4-Morpholinoethanesulfonic acid (MES), sodium chloride 
(NaCl), Guanidine Hydrochloride (GnHCl), Tris hydrochloride (Tris HCl), ammonium carbonate, 
dithiothreitol (DTT), iodoacetic acid, acetylated trypsin, sodium hydroxide (NaOH), hydrogen chloride 
(HCl), acetonitrile and trifluoroacetic acid (TFA) were all purchased from Sigma-Aldrich (Saint Quentin 
Fallavier Cedex, France). All reagents were certified of HPLC grade. 
2.2 Preparation and conditioning 
10 mg/mL infliximab solutions were sterilely prepared from Inflectra® powder for solution for 
infusion by adding water for injection to the medication vial, according to the manufacturer’s instructions 
using a sterile metal needle (Blunt Fill Needle 18G x 1 ½”, Becton Dickinson, Spain), under the laminar air 
flow of an ISO 4.8 microbiological safety cabinet. Solutions were then diluted to 0.4 and 2 mg/mL into 0.9 
NaCl infusion bags. 
2.3 Study design 
The prepared units were then stored in the dark for up to 30 days for the 10 mg/mL solutions and 
90 days for the 0.4 and 2 mg/mL solutions at controlled refrigerated temperature (Whirlpool refrigerator) 
at 5°C ± 2°C or in a climate chamber (BINDER GmbH, Tuttlingen, Germany) at 25°C ± 2°C and 60% residual 
humidity, until analysis. The units dedicated to the freeze-thawing study were frozen at -20°C ± 2°C for 60 
hours. 
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For the studies at 5°C and 25°C, samples were analysed in triplicate at D0, D7, D14, D30 and D90, 
except for 10 mg/mL samples for which D90 was not performed. For the freeze-thawing study, samples 
were analysed at D0 and after 60 hours freezing after a complete thawing, assessed visually. 
2.4 Analyses 
Infliximab solutions were subjected to a series of analysis to investigate physical, chemical and 
structural stability. Total protein quantification was also performed. Before all analyses, the 10 mg/mL 
samples were diluted to 0.4 mg/mL of infliximab in sodium chloride solutions, except for subvisible 
particle determination for which the samples were analysed without dilution, and for peptide mapping 
analysis during which the samples were analysed at 2 mg/mL. The 0.4 mg/mL and 2 mg/mL infliximab 
solution samples were analysed directly without dilution.  
2.4.1 Physical stability analysis 
2.4.1.1  Visual inspection 
The solutions were visually inspected under a white light in front of a matt black panel and a non-
glare white panel. Aspect and colour of the solutions were noted, and a screening for visible particles, 
haziness, or gas development was performed. 
2.4.1.2 Turbidimetry 
 Turbidity was evaluated by measuring the absorbance of the infliximab solutions at 320 nm and 
350 nm using a spectrophotometer UV/VIS/NIR Jasco V – 670 (Jasco France, Bouguenais, France) 
equipped with a single monochromator, a deuterium lamp (range 190 - 350nm) and a halogen lamp 
(range 330 – 2700 nm). The results were analysed using the provided software (Spectra manager II) 
An increase in the calculated aggregation index (AI) compared to the D0 reference is indicative of 
an increase of samples turbidity. 
Equation 1 : Estimation of turbidity by calculation of Aggregation Index (AI). A corresponds to 
absorbance at specified wavelengths (280 and 350 nm) 
   
    
         
       
An AI value <10 was considered to be acceptable [13,14] 
5 
 
2.4.1.3 Subvisible particles counting 
Subvisible particle counting was performed on a HIAC Royco 9703 (Hach Lange, Noisy le Grand, 
France) equipped with a HRLD 400 EC detector. 
Four successive measurements were carried out on a volume of 5 mL, and the first run was 
discarded. The results were expressed as the number of particles of size superior to 10 µm and superior 
to 25 µm, per mL of solution. For the 10 mg/mL solutions, the triplicates from each condition were 
pooled together in order to have a sufficient volume to perform the analysis according to the European 
pharmacopeia monography (2.09.19)[15]. 10 mg/mL solutions were compared to the limits indicated in 
the European Pharmacopoeia 2.09.19 monography for small volume parenterals : <6000 particles 
/container (10 µm particles) and < 600 particles / container (25 µm particles). Whereas 0.4 and 2 mg/mL 
solutions were compared to limits indicated in the European Pharmacopoeia  2.09.19 monography for > 
100 mL parenterals; <25 particles/mL equal to or greater than 10 µm and < 3 particles/mL equal to or 
greater than 25 µm [15]. Samples were considered to be conform if it didn’t statistically increase when 
compared to D0 values (Student test, α = 0.05) 
2.4.1.4 Nanoparticles size determination 
Dynamic Light Scattering (DLS) allows the estimation of the size of protein aggregates between 
0.3 nm and 10 µm. The particle size is obtained from the variation of intensity of light scattering due to 
Brownian motion of particles. Particle size was determined on 1 ml of each sample in clear disposable 
polystyrene cells by dynamic light scattering measurements, using a Zetasizer Nano ZS (Malvern 
Instruments SARL, Orsay Cedex, France). Each sample was automatically screened 3 times. The obtained 
size distribution was presented by percentage of intensity and must conform to reference (D0) profiles. A 
variation in size of less than 3 nm of the main peak’s hydrodynamic radius was considered as being 
acceptable. In parallel, the apparition of a peak different from infliximab main peak for which intensity 
percentage was superior to 10% was considered as being unacceptable. 
2.4.1.5 Size exclusion chromatography (SEC) 
Size exclusion chromatography allows the evaluation of monoclonal antibody aggregation or 
fragmentation. The chromatographic separation was performed by liquid chromatography (LC), using a 
LC-2010-A HT with integrated controller, pump, autosampler, oven and UV-VIS dectector (Shimadzu 
Corporation, Marne la Vallée, France). Two LC separation columns TSK - GEL® G3000SWXL columns (7.8 
mm x 30 cm x 5 µm, TOSOH Bioscience), purchased from Interchim (Montluçon, France) were used, 
mounted in series. A sample volume of 100 µl was injected into the system and then eluted using an 
isocratic flow (Na2SO4 0.1 M Na2HPO4 0.1 M and 0.05% m/w NaN3 in water, buffered at pH 7) at a 
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flowrate of 0.6 mL/min, at a set temperature of 25 ° C. The detection wavelength was set up at 280 nm. 
Obtained SEC chromatograms must conform to reference (D0) SEC chromatogram (monomer ≥98%). 
However, apparition of other species (oligomer or fragment) was followed, when applicable. 
2.4.2 Chemical stability analysis 
2.4.2.1 pH and osmolality 
pH measurements were made using a SevenMultiTM pH-meter with an InLabTM Micro Pro glass 
electrode (Mettler-Toledo, Viroflay, France). Osmolality was measured for each solution using an 
osmometer Model 2020 Osmometer® (Advanced instruments Inc, Radiometer, SAS, Neuilly Plaisance). 
pH measurements were considered to be acceptable if they did not vary by more than 1 pH unit 
from initial measure. Osmolality measurements are to be interpreted with regards to the potential 
modification of other parameters and for the purpose of this study were considered to be acceptable if 
they did not vary by more than 10 mosmol/kg from D0 values. 
2.4.2.2 Cation exchange chromatography (CEX) 
Cation exchange chromatography is used to separate different isoforms of infliximab. The 
chromatographic separation was performed by liquid chromatography (LC), using a LC-2010-AHT with 
integrated controller, pump, autosampler, oven and UV-VIS dectector (Shimadzu Corporation, Marne la 
Vallée, France). All analyses were performed on a TSKgel CM-STAT column (4.6 mm x 100 mm x 7 µm, 
TOSOH Bioscience), purchased from Interchim (Montluçon, France). Buffer A was prepared with 20mM 
MES, and buffer B was prepared with 20 mM MES, 0.5 M NaCl. For each buffer the pH was adjusted to 
5.6 using 1N NaOH solution. The injected sample volume was of 100 µL and elution parameters were the 
following:  flow rate of 1 mL/min using a gradient composed of 98% of phase A and 2% of phase B 
reaching 50% phase A and 50% phase B in 35 minutes, then the column was equilibrated with the initial 
mobile phase for 10 minutes between each analysis. Analysis temperature was set at 35°C. The detection 
wavelength was set up at 280 nm. 
Obtained CEX chromatograms must conform to reference (D0) CEX chromatogram. The 
distribution of each ionic variant was expressed in percentage of total area under curve (AUC). Any 
variation under 3% was considered to be acceptable. 
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2.4.3 Structural analysis 
2.4.3.1 Peptide mapping 
Peptide mapping allows the study of infliximab’s primary structure. 500 µL of the solution (250 µL 
for the 2 mg/mL solutions), were denatured with GnHCl (final concentration 6M) in 0,119 M Tris HCl 
buffer at pH=8.5 and reduced with 2 mM DTT. Denaturation and reduction were performed together for 
60 min at 37°C. Samples were then alkylated by 50 mM iodoacetic acid for 15 min at room temperature 
protected from light. Tris HCl buffer was removed by using a spin filter 10 kDa molecular weight cut-off 
(Millipore, Molsheim, France). After 20 min centrifugation at 4000 rpm, supernatant was completed up to 
3.5 mL with 100 mM ammonium carbonate buffer (pH = 7.6). Spin filters were centrifugated again 20 min 
at 4000 rpm. The digestion step was performed with an acetylated trypsin ratio 1:20 (Trypsin / Infliximab, 
weight/weight) for 14 h overnight at 37°C. Before chromatographic analysis, samples were recovered 
from digestion step and completed to 400µL with 0.1% TFA in water. The reaction was quenched by 
storing samples at 5°C inside the refrigerated autosampler, and 20µL of each sample were injected into 
the column. 
The chromatographic separation was performed by liquid chromatography (LC), using a LC-2030C 
with integrated controller, pump, autosampler, oven and UV-VIS dectector (Shimadzu Corporation, 
Marne la Vallée, France). The separation was performed on a C18 Nucleosil column (250 mm x 3 mm, 5 
µm, Macherey Nagel, France). Mobile phase was composed of 0.1% TFA in water (phase A) and 0.09% 
TFA in acetonitrile (phase B). Elution started with a gradient 95% phase A and 5% phase B. A linear 
gradient was run from 5% to 40% of phase B in 140 min. The flowrate was set to 1 ml/min and column 
oven temperature at 40°C. The detection wavelength was set up at 215 nm. A postrun treatment was 
done by subtracting the chromatogram of the trypsin solution. 
Obtained peptide mapping chromatograms must conform to reference (D0) chromatogram. 
Minor and unreproducible variations in the peptide mapping profile (eg. slight retention time variations, 
intensity variations) were considered to be acceptable. Major reproducible differences, like the 
appearance or disappearance of a peak, were considered to be unacceptable. 
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2.4.3.2 Second derivative Fourier Transform Infrared Spectroscopy (FTIR) 
The secondary structure of infliximab was monitored by second derivative FTIR in amide I region 
(1600 – 1700 cm-1) using an Avatar 320 (Nicolet, Thermo Electron, Courtaboeuf Cedex, France) equipped 
with a transmission cell with 25 mm BaF2 windows. All acquisitions were treated with Omnic software. For 
FTIR analysis, samples of each concentration were concentrated up to 40 mg/mL using a spin filter 10kDa 
molecular weight cut-off (Millipore, Molsheim, France). 
Obtained FT-IR spectra must conform to reference (D0) profiles. A shift in maxima’s and minima’s 
wavenumbers inferior to 2 cm-1 was considered to be acceptable. 
2.4.3.3 Second derivative UV spectroscopy 
Tertiary structure was studied by second derivative UV spectroscopy. All spectrums were 
acquired on a Spectrophotometer UV/VIS/NIR Jasco V-670 (Jasco France, Bouguenais, France), using 1 cm 
pathlength quartz cuvettes and the measurement wavelength range was set between 250 and 350 nm. 
All acquisition data were treated with Spectra manager II software. 
Obtained second derivative ultraviolet spectra must conform to reference (D0) spectra. A shift in 
maxima’s and minima’s wavelengths inferior to 2 nm was considered to be acceptable. 
2.4.4 Total protein quantification 
Protein content per vial was estimated by measuring absorbance at 280 nm [16] of Inflectra® 10 
mg/mL solutions diluted to 0.4 mg/mL. All data were acquired on a spectrophotometer UV/VIS/NIR Jasco 
V-670 (Jasco France, Bouguenais, France), using 1 cm pathlength quartz cuvettes. Protein content was 
calculated using the Beer-Lambert law. According to the manufacturer instructions, protein content was 
considered to be acceptable when between 90% and 110% of theoretical concentration. 
2.4.5 Data analysis – acceptability criteria 
The study was conducted following methodological guidelines issued by the International 
Conference on Harmonisation for stability studies (ICH guidelines for stability [9,11] and specifications for 
Biotechnological/Biological products [10]), Bardin et al., 2011 [8], the European Pharmacopeia [17] and 
recommendations issued by the French Society of Clinical Pharmacy (SFPC) and the Evaluation and 
Research Group on Protection in Controlled Atmosphere (GERPAC) [18]. , French Society and European 
Society of Oncology Pharmacy[19]. NHS guidance [20] and INFLECTRA® specifications (provided by 
Pfizer®) were also taken into account. 
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3. Results 
3.1 Visual inspection 
At D0, all infliximab samples were limpid, colourless and no visible particles were observed. 
Throughout the study, no evolution was noticed for the samples stored at 5°C and 25°C. After complete 
thawing, no evolution from D0 was noticed with any storage condition. 
 
3.2 Turbidity 
Throughout the study, for each concentration and conservation condition, the AI remained within 
acceptability criteria, with a maximum of 1.761, 0.640 and 0.660 for respectively the 10 mg/mL, 2 mg/mL 
solutions and 0.4 mg/mL infliximab solutions. For every condition, AI values remained below acceptability 
limit even if there was an important variation between samples. 
3.3 Subvisible particles counting 
Larger than 10 µm subvisible particle count was out of acceptability criteria only after freezing-
thawing of 0.4 mg/mL infliximab solutions (Figure 1). At D0, >25 µm subvisibles particles counting 
revealed 9 ± 4 particles/mL for 0.4 mg/mL infliximab solutions, 1 ± 0 particles/mL for 2 mg/mL infliximab 
solutions and  24 particles/mL in 10 mg/mL infliximab solutions. The number of particles was more 
important with 10 mg/mL samples than with diluted solutions, respectively 127 and 24 particles/mL 
superior to 10 µm and superior to 25 µm. For each temperature and analytical time, the number of 
particles/mL did not significantly increase. 
 
Figure 1 : Number of particles > 10 µm for 0.4 mg/mL and 2 mg/mL infliximab solutions in 0.9% 
NaCl infusion bags at each storage temperature (mean ± SD, n=3) 
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The counting of subvisible particles of size superior to 10 µm and superior to 25 µm in diluted 
solutions (0.4 and 2 mg/mL) was over European Pharmacopeia limit (respectively 25 particles /mL and 3 
particles /mL) while it remained within European Pharmacopeia limits for the 10 mg/mL solutions as their 
nominal volume was lower than 100 mL (respectively 6000 particles/container and 600 
particles/container). 
3.4 Nanoparticles size determination 
Infliximab nanoparticles sizes estimated by DLS are shown in Table 1. Hydrodynamic diameter 
was out of acceptability criteria only after freeze-thawing of 10 mg/mL infliximab solutions, as an increase 
of 3.17 nm was noticed after a single freeze-thawing cycle. 
Table 1 : Infliximab nanoparticles hydrodynamic diameter evolution over time and storage 
conditions for each studied concentration estimated by DLS (ND: not determined).   
 
10 mg/mL 2 mg/mL 0.4 mg/mL   
 Storage 
time 
(days)  
mean size ± SD 
(nm) 
mean size ± SD 
(nm) 
mean size ± SD 
(nm) 
Mean PDI 
± SD 
  Freezing   
D0 12.22 ± 2.66 16.83 ± 5.06 12.58 ± 2.49 0.202 ± 0.048 
D3 15.39 ± 5.76 17.68 ± 4.86 14.38 ± 5.00 0.190 ± 0.043 
  5°C   
D0 13.45 ± 2.69 16.83 ± 5.06 12.58 ± 2.49 0.203 ± 0.049 
D7 12.66 ± 3.01 16.22 ± 4.91 13.56 ± 3.94 0.160 ± 0.023 
D14 14.91 ± 5.80 16.81 ± 5.54 12.62 ± 2.82 0.193 ± 0.049 
D30 13.58 ± 5.63 16.53 ± 5.29 12.98 ± 3.76 0.189 ± 0.048 
D90 ND 17.78 ± 5.83 12.82 ± 3.81 0.156 ± 0.035 
  25°C   
D0 13.45 ± 2.69 16.83 ± 5.06 12.58 ± 2.49 0.21 0± 0.041 
D7 12.88 ± 3.88 16.41 ± 4.63 12.61 ± 3.27 0.160 ± 0.023 
D14 13.76 ± 4.86 16.65 ± 5.01 12.72 ± 2.82 0.170 ± 0.052 
D30 12.73 ± 3.48 16.72 ± 5.33 13.23 ± 4.48 0.174 ± 0.045 
D90 ND 17.40 ± 5.61 13.00 ± 2.92 0.162 ± 0.025 
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3.5 Size exclusion chromatography 
The main peak, corresponding to infliximab monomeric form (elution time (et) = 27.3 min ± 0.02 
min) remained above 98% of total Area Under Curve (AUC) throughout the studies for all conditions. A 
second peak (et = 23.2 min ± 0.2 min) corresponding to a high molecular weight polymer (HMWP) was 
observed from D0 onwards but did not significantly vary overtime for any of the conditions. However, a 
fragment was  detected with a et = 33.6 min ± 0.1 min, and its  AUC percentage increased overtime for 
samples of all three concentrations when stored at 25°C, but not for those stored at 5°C and at -20°C (the 
peak remained unquantifiable) (see supplementary data, Table A). As an example, SEC chromatograms of 
the 0.4 mg/mL infliximab solutions at D0 are compared to chromatograms of the last analytical of each 
storage condition (D90 for storage at 5°C and 25°C and D3 after freezing) in Figure 2. The main peak 
corresponding to infliximab monomeric form represented 99.29% ± 0.03 % of total AUC. At D90 of the 
25°C storage, the fragmented form reached its maximum of 0.48% ± 0.08% of total AUC while no 
variation from D0 was observed after storage at 5°C or -20°C.  
Monomeric form at D0 for infliximab solutions at 2 mg/mL and 10 mg/mL were respectively of 
99.15% ± 0.00% and 99.19% ± 0.02% and the increase in fragmented form was observed for all 25°C 
storage conditions with respective values of 0.13% ± 0.00% and 0.10% ± 0.00% at D90 while no 
modification was observed after storage at 5°C or -20°C. 
 
Figure 2 : SEC profile evolution of 0.4 mg/mL infliximab solutions at D0 compared to D90 after a 90 
days storage at 5°C and 25°C and after a freeze-thawing cycle of 3 days 
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3.6 pH and osmolality 
Initial pH values for the different conditions are shown in Table 2. For all studies, no variations of 
more than ± 0.27 pH units and 4.33 mosmol/kg were observed from D0 values onwards. Throughout the 
study and for both conservation conditions, obtained pH and osmolality results meet acceptability criteria 
(no significant variation). 
Table 2 : pH and osmolality values at D0 for every conditioning condition (mean ± SD, n=3) 
  
Mean pH at D0 ± SD 
Mean osmolality at D0 ± SD 
mosmol/kg 
10 mg/mL in original glass vials 6.98 ± 0.07 280.33 ± 3.06 
0.4 mg/mL in NaCl bags 6.92 ± 0.05 280.33 ± 0.58 
2 mg/mL in NaCl bags 7.09 ± 0.01 261.67 ± 1.53 
 
3.7 Cation exchange chromatography 
CEX chromatograms presented a specific profile with 6 different peaks. None of the studied 
conditions led to new acidic or basic variants appearance. As an example, CEX results of 0.4 mg/mL 
infliximab solutions are shown in Figure 3. A significant decrease of peak 4 (-5.36%) and increase of peak 
1 (+5.47%) was simultaneously observed at D90 when sample were stored at 25°C. Modifications until D30 
included were not significant. When stored at 5°C, peak proportion of total AUC did not vary by more 
than 2.75%. A similar evolution profile was observed for other storage and concentration conditions. The 
10 mg/mL solutions at 25° condition showed a coupled decrease of peak 4 (-3.34%) and increase of peak 
1 (+3.77%) from D14 included.  
After a freeze-thawing cycle, a decrease of peak 4 and an increase of peak 1 percentage of total 
AUC was observed when 10 mg/mL infliximab samples were frozen for 3 days. CEX chromatograms of 0.4 
mg/mL Infliximab solutions did not show any significant variation from D0 (Figure 3. B).  
When stored at 5°C, all three studied infliximab concentrations remained within acceptability 
criteria throughout the study (no variation of variants percentage). 
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Figure 3 : Cation Exchange chromatograms at each analytical time of 0.4 mg/mL infliximab solutions 
stored at 25°C (A), evolution of peaks percentage from total AUC (mean ± SD, n=3) for the 5°C (B) and 25°C 
(C) storage condition, comparison of each peaks percentage of total AUC at the final analytical time for 
each storage condition of 0.4 mg/mL infliximab solutions (D) and 10 mg/mL infliximab solutions (E). 
 
3.8 Peptide mapping 
Peptide mapping chromatograms of 10mg/mL infliximab solutions at D0 is shown in Figure 4. 
Despite being very similar, minor modifications from D0 profile were observed at D30 for both 
temperature conditions (supplementary data, figure A). After freezing, peptide map was qualitatively 
different from D0 (supplementary data, figure B) 
For all other conditions of temperature and concentration, peptide map was not significantly 
different from D0 at any time.  
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Figure 4 : peptide mapping chromatogram of 10 mg/mL infliximab solutions at D0. (n=3, black, blue 
and pink chromatograms corresponding to the triplicate)  
 
3.9 Second derivative FT-IR 
Second derivative FTIR spectra of 0.4 mg/mL infliximab solutions at D0 and compared to those at 
the final analytical time of each condition is shown in Figure 5. No modification was observed from D0 to 
D90 or after a freeze-thawing cycle, nor for any other concentration and storage conditions at any time. 
 
Figure 5 : Second derivative FTIR spectra of 0.4 mg/mL infliximab solutions at the final analytical 
time of each temperature condition. 
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3.10 Second derivative UV spectroscopy 
Second derivative UV spectra of 0.4 mg/mL infliximab solutions at D0 and compared to those at 
the final analytical time of each condition is shown in Figure 6. No modification was observed from D0 to 
D90 or after a freeze-thawing cycle, nor for any other concentration and storage conditions at any time.  
 
Figure 6 : Second derivative UV spectra of 0.4 mg/mL infliximab solutions at the final analytical time 
of each temperature condition. 
3.11 Total protein quantification 
Quantification for every preparation and storage conditions is shown in Figure 7. For 0.4 mg/mL 
infliximab solutions concentration was respectively of 0.39 ± 0.01 mg/ at D0. For 2 mg/mL infliximab 
solutions, concentration was 1.75 ± 0.04 mg/mL and for 10 mg/mL infliximab solutions, the result is 
expressed as the amount of protein/vial and was of 9.05 ± 0.79 mg/vial at D0.  
Over the study, for each concentration and temperature condition, results remained between 
90% and 110% of theoretical concentration. 
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Figure 7 : Total protein quantification of infliximab solutions: 10 mg/mL (A), 0.4 mg/mL (B), and 2 
mg/mL (C) for each conservation temperature condition 
3.12 Synthesis 
All signs of instability observed are presented in Table 3.   
Table 3 : Summary of stability result for each analytical technique and conditions.  
  10 mg/mL 2 mg/mL 0.4 mg/mL 
  Freezing 5°C 25°C Freezing 5°C 25°C Freezing 5°C 25°C 
Physical 
Visual exam         
Turbidity         
HIAC         
DLS         
SEC 
         
 
oligomers at 
D14 
 
oligomers at 
D14 
  
oligomers at 
D14 
Chemical 
pH/osmo          
CEX   
 
7 days 
  
 
30 days 
  
 
30 days 
Structural 
Peptide 
mapping 
 
 
14 days 
 
14 days 
      
SD-FTIR          
SD-UV          
 
 : Absence of instability at the end of the study   : Instability observed  x Days : last analytical time without instability 
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4. Discussion 
Our study presents new information about the stability of concentrated and diluted infliximab 
solutions, pertinent to regular pharmaceutical and clinical use. A large panel of analytical techniques 
was used to assess the effect of storage temperature and dilution on the physicochemical stability of 
infliximab solutions as recommended by the international guidelines [11–17]. In forced degradation 
studies physical degradation is usually the main issue [21], even if it can be associated with chemical 
degradation under some conditions [22]. However, in this long term storage study, chemical stability 
appeared to be the most critical point, as after 90 days storage at 25°C, important chemical 
modifications and minor physical instabilities were revealed by CEX and SEC for both 0.4 and 2 mg/mL 
solutions, however storage at 5°C allowed infliximab to remain physicochemically unchanged for up to 
90 days included. Freezing caused physical degradation (increased particle levels) for all three 
concentrations. Stability appeared to be dilution dependent, in addition to temperature dependent. 
For the 10 mg/mL infliximab solutions, obtained data is in favour only a 7 days physicochemical 
stability when stored at 25°C after reconstitution with water for injection in original glass vials. When 
stored at 5°C, the data is in favour of an extended stability of 14 days. 0.4 mg/mL and 2 mg/mL 
infliximab solutions diluted in NaCl and stored in Polyolefin (Polypropylene PP) bags were stable up to 
30 days at 25°C and 90 days at 5°C 
Aggregate formation is normally the main critical point limiting mAbs stability in solutions, and 
has also been shown to occur after freeze-thawing stress of monoclonal antibodies [23]. Four 
analytical techniques, that complement each other, were used to assess the aggregation level of 
infliximab solutions. Sub-visible particles over 10 µm and over 25 µm were counted by light 
obscuration (HIAC) and nanoparticles between 0.3 nm and 10 µm were assessed by DLS. SEC was also 
used to explore aggregation, since this Liquid Chromatography (LC) method is able to separate mAbs 
monomeric form from the polymeric form (dimeric or more) and fragments. To complete aggregate 
formation study, turbidity was assessed by calculating an aggregation index based on absorbance at 
280 nm and 350 nm. Without aggregation, absorbance at 350 nm is almost null, but when aggregates 
are presents in solution, the UV beam is deflected leading to an increase in absorbance. Those four 
analytical techniques allowed us to have a global vision of infliximab’s aggregation potential, but mAbs 
stability is not only limited to physical issues. Chemical stability was assessed by CEX which is an LC 
method separating mAbs charge variants, mainly resulting from the manufacturing process. 
Osmolality and pH are part of the chemical stability and were followed because of the clinical impact 
they could have during the infusion to the patient. Beside the clinical aspect, pH variations can be 
responsible of mAbs degradation [24], especially leading to a potential aggregation. In this work 
primary structure was assessed by performing a peptide map, a chromatographic separation of 
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peptides stemming from an enzymatic digestion. Secondary and tertiary structures were characterized 
by spectroscopic methods, respectively SD-FTIR and SD-UV. However, circular dichroism and 
fluorescence spectroscopy could have been employed as alternative techniques to assess secondary 
structure and conformational changes. However, it has been shown that even if circular dichroism can 
provide complementary information about secondary structure, it is not more efficient than SD-FTIR 
to highlight small conformational changes that are likely to happen during a stability study [25]. 
Visual examination has not shown any differences throughout the studies when samples were 
stored at 5°C. This result was confirmed by turbidity and subvisibles particles counting analysis, which 
did not show any increase overtime, indicating the absence of large aggregate formation. The number 
of particles larger than 10 µm and 25 µm was over generally above European Pharmacopeia 
acceptability criteria [15] for 0.4 and 2 mg/mL solutions, even at D0, but since the manufacturer 
recommends to infuse infliximab with a infusion set equipped with an inline 0.22 µm filter which 
would retain the particles, the clinical impact of such subvisible particles might be negligible as they 
would be retained before administration. DLS results did not highlight the formation of dimer or 
smaller than 1 µm aggregates since no particles with a significant higher hydrodynamic diameter were 
detected. As previous studies have shown before [26], hydrodynamic diameter was lower with 0.4 
mg/mL samples than with 2 mg/mL (10 mg/mL samples were diluted to 0.4 mg/mL before analysis 
which explains why they were not larger than 2 mg/mL particles).  
SEC results highlighted the presence of HMWP from D0 regardless of the conditions, probably 
dimers and other size variants that were hardly separable. Those HMWP have already been 
highlighted by studies [26] made on another infliximab biosimilar (REMSIMA®). SEC also detected a 
fragment formation, which was present but under the quantification limit at D0 for the 0.4 mg/mL 
concentrations. Yet, this fragment increased overtime for every concentration condition at 25°C, but 
not at 5°C. Despite increasing fragment percentages, the monomeric form remained over 99% of total 
AUC. Without official recommendations for acceptable degradation of monoclonal antibodies, the 
critical threshold used was the one set up by the manufacturer (monomer >98% of total AUC). None 
of the analytical techniques used for physical stability evaluation indicated the formation of 
aggregates during any of the studied conditions. Previous internal intentional degradation studies 
(data not shown) highlighted that some mAbs degradation products (especially fragments) were 
hardly separable by SEC. The use of two columns mounted in series allowed us to increase selectivity 
of the SEC method without using smaller particles packed columns, which even if they possess several 
advantages like better peak resolution and separation between aggregates and native protein peaks 
[27], require the use of ultra-high pressure chromatographic systems, whilst using UV detection that 
was the only option available at our laboratory. However, fluorescence detection based SEC (or CEX) 
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would avoid some of the limits of UV based detection, especially by increasing sensitivity which is 
major issue for monoclonal antibodies 
Infliximab presented a CEX profile with 6 peaks sufficiently resolved, the 7th that had been 
described in other studies [26,28] was visible (between peak 5 and 6 of these studies) but not 
quantifiable. Mobile phase pH was adjusted to 5.6 and could explain the differences observed 
between our chromatograms and other studies. Indeed, acidic variants were better resolved with a pH 
at 5.6 while basic variants were better visualized at pH = 6.5 [29]. In order to make our CEX results 
comparable to studies already performed with the infliximab biosimilar REMSIMA, the CEX analysis 
was performed by injecting the intact antibody. However, an enzymatic digestion by papain which split 
Fc and Fabs of monoclonal antibodies might provide more information about the localisation of 
potential charge variants. Moreover, the papain digestion could also increase the selectivity of the 
method by increasing the separation between variants. Another way of increasing specificity is to 
separate variants with a semi-preparative column, then analyse each fraction one by one. 
Charge variants were present even at D0 and corresponded to post-translational modifications 
resulting in infliximab with zero, one or two C-terminal Lysine associated with a variation of charged 
glycans [28]. An equilibrium between all those variants was observed at D0. During the studies, no 
new acidic or basic variants appeared, but the variation observed (increase of acidic variant 1) for all 
concentration conditions when stored at 25°C was a sign a chemical instability. The 3% threshold 
corresponded to the limit where variation was considered to be significantly different from analytical 
variations. Our studies have shown that chemical instability was the principal stability limitation of 
infliximab solutions during long term storage at 25°C. Significant modifications arose faster with the 10 
mg/mL conditions (14 days against 90 days for other conditions), so diluting a mAb solution may be a 
way to increase chemical stability. However, dilution will also diluted excipients, some of which are 
known to have a stabilizing effect, like surfactants [24]. On the other side, 10 mg/mL samples were 
reconstituted in water for injection while samples at lower concentrations were diluted in 0.9% NaCl 
bags, and it had been shown that the ionic strength may interfere with monoclonal antibodies stability 
[30]. 
 Modifications in the primary structure were observed through peptide mapping analysis. A 
minor modification was noticed only in the 10 mg/mL in glass vials conditions after D30. Even though 
we were not able to accurately characterize the sort of modifications of the peptide map (oxidation, 
deamidation) without using LC-MS method, LC was sensitive enough to perform a qualitative 
comparison between samples at D0 and samples after storage. A variation in primary structure is 
often a cause of physical instability, fragmentation or aggregation. Considering the absence of 
instability it is not surprising that primary structure remained unchanged during the study for all 
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concentration and temperature conditions. However, if the units had been exposed to light during the 
study, maybe certain oxidation modifications might have noticed, as light as been shown to catalyse 
some modifications [31]. 
Secondary and tertiary structures were assessed respectively by SD-FTIR and SD-UV 
spectroscopy and no sign of instability was highlighted. Variations observed with CEX could have been 
related to a structural modification, but they were either below the sensitivity limits of spectroscopic 
methods either not related, as Jasper C. et al [23] have shown in FTIR. However, Jasper C. et al. [25] 
did show that variations in SEC and CEX can be not related to a modification in SD-FTIR spectrum. 
Previous studies made with other infliximab biosimilars [27,31] assessed the stability of diluted 
solutions over a study period of 30 days. This study has shown that infliximab diluted in NaCl 
polyolefin bags were physically and chemically stable up to 90 days when stored at 5°C, and 30 days at 
25°C. 
Physical and chemical signs of instability were detected when stressing 10 mg/mL infliximab 
solutions by freeze-thawing. Variations of nanoparticles hydrodynamic diameter were observed in DLS 
when infliximab samples were frozen at 10 mg/mL but were absent when for 0.4 mg/mL and 2 mg/mL 
solutions. This could be explained by aggregation (possible formation of dimers or other HMWP) 
slightly impacting overall particle size, without modifying any other structural aspect. This result could 
have been confirmed by SEC but the amount of formed aggregates was probably under the limit of 
detection (LOD) of the assay. Chemical stability was assessed by CEX and highlighted a correlated 
variation of two peaks corresponding to the main peak with no C-terminal Lysine [26] (peak 4) and an 
unidentified acidic variant (peak 1). These modifications were not correlated to a pH variation and 
suggested a chemical instability that could be part of a possible aggregation mechanism predicted by 
DLS. To complete physicochemical analysis, a structural analysis was performed. Secondary and 
tertiary structures were assessed respectively by SD-FTIR and SD-UV spectroscopy. None of these 
analytical techniques showed any sign of instability. Peptide mapping was used to characterize 
primary structure, and highlighted an unexpected change in the complete mapping of infliximab 
solutions at 10 mg/mL in glass vials. An analysis of the peptide map by LC-MS could have allowed us to 
determine what kind of degradation the peptides underwent and determine if the modification of the 
peptide map was related or not to the potential aggregation phenomenon.  
However, infliximab solutions at 0.4 and 2 mg/mL did not show any sign of chemical instability and 
hydrodynamic did not vary after freezing. HIAC results suggested an increase in subvisibles particles 
after freeze-thawing of 0.4 and 2 mg/mL infliximab solutions, whilst subvisibles particles levels 
remained unchanged for 10 mg/mL solutions. This increase was correlated with a slight increase in 
turbidity (but remaining within acceptability criteria) and with SEC results, as HMWP increased in both 
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cases (again remaining within acceptability criteria), and could therefore be in favour of mild 
aggregation. Alternatively, subvisible ice residues in the solutions after the thawing protocol cannot be 
excluded and may have caused the increased subvisible particle levels, however such a phenomenon 
wouldn’t explain the alteration of the other parameters. 
 Aggregation phenomenon is well known for occurring after freeze-thawing stress of 
monoclonal antibodies [23]. 10 mg/mL solutions were reconstituted with water for injection only, thus 
their ionic strength was negligible. It has already been shown that an increase in salt concentration 
increases monoclonal antibodies Antigen-binding fragment [32], this results suggested that ionic 
strength could also prevent aggregation for infliximab solutions after freeze-thawing. The level of 
aggregation has been shown to be dependent of antibody concentration [23]. So the potential 
aggregation observed with 10 mg/mL infliximab solutions could be a combination of both ionic 
strength and concentration differences compared to the 0.4 and 2 mg/mL solutions, in a freeze-
thawing stress situation.  
An accidental freezing could happen during conservation, and yet the results of this study 
suggested a limited stability and no use after freezing should be accepted, especially for 10 mg/mL 
infliximab solutions. Further studies will allow determining the instability mechanism by performing 
harder stress conditions and increasing suspected instability signs. 
The global impact of ambient temperature storage was observed for all conditions, as CEX and 
SEC chromatograms highlighted respectively a chemical and physical instability of infliximab molecules 
when samples were stored at 25°C. However, differences in stability were also spotted between 
concentrated (10 mg/mL) and diluted solutions (0.4 and 2 mg/mL) for the same temperature 
condition. Those differences could be explained by the sample concentration and the reconstitution 
solvent (for 10 mg/mL solutions the solvent was water for injection, whereas NaCl 0.9% was the main 
diluent for the 0.4 mg/mL and 2 mg/mL solutions). It has been shown that ionic strength has a 
stabilizing effect on the conformational and chemical stability of the fab fragment [33], and it can 
therefore be hypothesized that a possible way of increasing 10 mg/mL infliximab stability would be to 
prepare it with a saline solution and not with water for injection. The container itself (glass vials or 
polyolefin bags) may also play a role in infliximab solutions stability. 
 
The assessment of physicochemical and structural properties is a good indicator to estimate 
mAbs stability, and we can suppose that infliximab binding to TNF will not be affected if 
physicochemical and structural properties are unchanged. Further biological effectiveness and 
immunogenicity studies will be needed to confirm that administration to patients is completely safe 
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after long term storage. The reconstitution of infliximab solutions was performed under aseptic 
conditions, minimizing the risk of contamination but microbiological studies will be needed to extend 
long term storage recommendations. In clinical use conditions, stability of reconstituted and diluted 
infliximab solutions is set up to 24h for both infliximab biosimilars (according to summary of product 
characteristics of both REMSIMA®[34] and INFLECTRA®[35]), limited by a hypothetically short 
microbiological stability. Due to the high cost of infliximab, an extended stability is relevant for 
hospital pharmacies and particularly in centralized reconstitution units since infliximab solutions 
preparation could be optimized, and drug wastage reduced. Studies performed on another infliximab 
biosimilar (REMSIMA®) have shown that infliximab diluted solutions were stable at least 7 days when 
diluted in NaCl bags [29,36], but freshly reconstituted vials, and solutions in infusion bags diluted from 
an aged vials haven’t been studied to our knowledge.  
5. Conclusion 
A complete characterization of an infliximab biosimilar physicochemical and structural properties was 
performed during this study. This stability study highlighted that chemical instability was the main 
stability limitation. The impact of storage temperature was confirmed, as infliximab solutions were 
more stable when stored at 5°C than at 25°C; diluted solutions at 0.4 and 2 mg/mL were more stable 
than 10 mg/mL solutions. Both dilution and temperature had an impact on stability, but their 
respective roles remain to be precisely determined. 
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